المؤلفون: Д. Л. Строяковский, Н. Х. Абдулоева, Л. В. Демидов, Н. В. Жукова, А. В. Новик, К. В. Орлова, И. В. Самойленко, Г. Ю. Харкевич, И. А. Утяшев, А. Н. Юрченков

المصدر: Malignant tumours; Том 14, № 3s2-2 (2024); 300-329 ; Злокачественные опухоли; Том 14, № 3s2-2 (2024); 300-329 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: анти CTLA4, мутация в гене BRAF, иммунотерапия, анти-PD1

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1393/998; https://www.malignanttumors.org/jour/article/view/1393

الاتاحة: https://www.malignanttumors.org/jour/article/view/1393
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.2-12

المؤلفون: Д. Л. Строяковский, Н. Х. Абдулоева, Л. В. Демидов, Н. В. Жукова, А. В. Новик, К. В. Орлова, С. А. Проценко, И. В. Самойленко, Г. Ю. Харкевич, А. Н. Юрченков

المصدر: Malignant tumours; Том 13, № 3s2-1 (2023); 291-310 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 291-310 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: анти-CTLA4, мутация в гене BRAF, иммунотерапия, анти-PD1

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1217/851; https://www.malignanttumors.org/jour/article/view/1217

الاتاحة: https://www.malignanttumors.org/jour/article/view/1217
https://doi.org/10.18027/2224-5057-2023-13-3s2-1-291-310

المؤلفون: С. А. Проценко, Н. Ю. Антимоник, М. Ф. Баллюзек, Л. М. Берштейн, Н. В. Жукова, А. В. Новик, Д. А. Носов, Н. Н. Петенко, А. И. Семенова, В. А. Чубенко, Г. Ю. Харкевич, Д. И. Юдин

المصدر: Malignant tumours; Том 12, № 3s2-2 (2022); 203-241 ; Злокачественные опухоли; Том 12, № 3s2-2 (2022); 203-241 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: лечение, иммуноопосредованные нежелательные явления

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1074/770; https://www.malignanttumors.org/jour/article/view/1074

الاتاحة: https://www.malignanttumors.org/jour/article/view/1074
https://doi.org/10.18027/2224-5057-2022-12-3s2-203-241

المؤلفون: С. А. Проценко, Н. Ю. Антимоник, Л. М. Берштейн, Н. В. Жукова, А. В. Новик, Д. А. Носов, Н. Н. Петенко, А. И. Семенова, В. А. Чубенко, Г. Ю. Харкевич, Д. И. Юдин

المصدر: Malignant tumours; Том 10, № 3s2-2 (2020); 168-199 ; Злокачественные опухоли; Том 10, № 3s2-2 (2020); 168-199 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: лечение, иммуноопосредованные нежелательные явления

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/801/565; https://www.malignanttumors.org/jour/article/view/801

الاتاحة: https://www.malignanttumors.org/jour/article/view/801
https://doi.org/10.18027/2224-5057-2020-10-3s2-50

المؤلفون: Д. А. Носов, Б. Я. Алексеев, М. И. Волкова, О. А. Гладков, А. М. Попов, Г. Ю. Харкевич

المصدر: Malignant tumours; Том 10, № 3s2-1 (2020); 533-541 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 533-541 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: циторедуктивная нефрэктомия, иммунотерапия, ингибиторы m-TOR, ингибиторы VEGFR

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/780/544; https://www.malignanttumors.org/jour/article/view/780

الاتاحة: https://www.malignanttumors.org/jour/article/view/780
https://doi.org/10.18027/2224-5057-2020-10-3s2-31

المؤلفون: I. V. Samoylenko, Ya. I. Zhulikov, G. Yu. Kharkevich, N. N. Petenko, L. V. Demidov, И. В. Самойленко, Я. А. Жуликов, Г. Ю. Харкевич, Н. H. Петенко, Л. В. Демидов

المصدر: Malignant tumours; Том 8, № 3 (2018); 78-85 ; Злокачественные опухоли; Том 8, № 3 (2018); 78-85 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: иммунотерапия, nivolumab, anti-PD-1, immunotherapy, ниволумаб, анти-PD-1

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/565/401; Robert C., Thomas L., Bondarenko I., O’Day S., Weber J., Garbe C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011. Vol. 364 (26). P. 2517–2526. PMID: 1639810. DOI:10.1056/NEJMoa1104621.; Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011. Vol. 480 (7378). P. 480–489. PMID: 22193102. DOI:10.1038/nature10673.; Kaufman H. L., Kirkwood J. M., Hodi F. S., Agarwala S., Amatruda T., Bines S. D. et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat. Rev. Clin. Oncol. 2013. Vol. 10 (10). P. 588–598. PMID: 23982524. DOI:10.1038/nrclinonc.2013.153.; Hodi F. S., O’Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010. Vol. 363 (8). P. 711–723. PMID: 20525992. DOI:10.1056/NEJMoa1003466.; Schadendorf D., Hodi F. S., Robert C., Weber J. C., Margolin K., Hamid O. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015. Vol. 33. P. 1889–1894. PMID: 25667295. DOI:10.1200/JCO.2014.56.2736.; Wolchok J. D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J. J., Cowey C. L. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017. Vol. 377 (14). P. 1345–1356. PMID: 28889792. DOI:10.1056/NEJMoa1709684.; Larkin J., Minor D., D’Angelo S., Neyns B., Smylie M., Miller W. H. et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J. Clin. Oncol. 2018. Vol. 36 (4). P. 383–390. PMID: 28671856. DOI:10.1200/JCO.2016.71.8023.; Weber J. S, D’Angelo S. P., Minor D., Hodi F. S., Gutzmer R., Neyns B. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015. Vol. 16 (4). P. 375–384. PMID: 25795410. DOI:10.1016/S1470–2045(15)70076‑8.; Ribas A., Hamid O., Daud A., Hodi F. S., Wolchok J. D., Kefford R. et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016. Vol. 315 (15). P. 1600–1609. PMID: 27092830. DOI:10.1001/jama.2016.4059.; Specenier P. Nivolumab in melanoma. Expert Rev. Anticancer Ther. 2016. Vol. 16 (12). P. 1247–1261. PMID: 27776441. DOI:10.1080/14737140.2016.1249856.; https://www.malignanttumors.org/jour/article/view/565

الاتاحة: https://www.malignanttumors.org/jour/article/view/565
https://doi.org/10.18027/2224-5057-2018-8-3-78-85

المؤلفون: B. Y. Alexeev, A. V. Alyasova, M. I. Volkova, S. L. Gutorov, V. B. Matveev, A. M. Popov, I. G. Rusakov, G. Y. Kharkevich, Б. Я. Алексеев, А. В. Алясова, М. И. Волкова, С. Л. Гуторов, В. Б. Матвеев, А. М. Попов, И. Г. Русаков, Г. Ю. Харкевич

المصدر: Malignant tumours; № 3 (2017); 89-92 ; Злокачественные опухоли; № 3 (2017); 89-92 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: ленватиниб, lenvatinib

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/395/342; Motzer R. J., Escudier B., McDermott D. F. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 2015 Nov 5; Vol. 373 (19), pp. 1803–1813. DOI:10.1056 / NEJMoa1510665. Epub 2015 Sep 25.; Choueiri T. K., Escudier B., Powles T. et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 2015 Nov 5, Vol. 373 (19), pp. 1814–23. DOI:10.1056 / NEJMoa1510016.; Motzer R. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol., 2015, Vol. 16, pp.:1473–1482.; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer version 2.2017 – October 31, 2016. Available at: https://www.nccn.org / professionals / physician_gls / pdf / kidney. pdf.; Клинические рекомендации по лечению рака паренхимы почки у взрослых, утверждены Российским обществом урологов, подготовлены совместно со специалистами Российского общества онкоурологов и Ассоциации онкологов России. Доступны на сайте Министерства Здравоохранения Российской Федерации. URL: http://cr.rosminzdrav.ru / schema. html?id=87# / text. [Klinicheskie rekomendatsii po lecheniyu raka parenkhimy pochki u vzroslykh, utverzhdeny Rossiyskim obshchestvom urologov, podgotovleny sovmestno so spetsialistami Rossiyskogo obshchestva onkourologov i Assotsiatsii onkologov Rossii. Available at: http://cr.rosminzdrav.ru / schema. html?id=87# / text (In Russ.)].; Инструкция по медицинскому применению препарата Афинитор® (эверолимус): РУ ЛП – 002288 от 28.10.2013. [Instructions for the medical use of the drug Afinitor® (everolimus): RU PL – 002288 dated 10.28.2013 (In Russ.)].; Инструкция по медицинскому применению препарата Инлита® (акситиниб): РУ ЛП-003983 от 29.11.2016. [Instructions for the medical use of the preparation of Inlita® (axitinib): RU LP-003983 dated 11.29.2016 (In Russ.)].; Инструкция по медицинскому применению препарата Опдиво® (ниволумаб): РУ ЛП – 004026 от 22.12.2016 [Instructions for the medical use of the drug Opdivo® (nivolumab): RU PL – 004026 dated 12.12.2016 (In Russ.)].; Инструкция по медицинскому применению препарата Ленвима® (ленватиниб): РУ ЛП – 003398 от 29.12.2015, с изменениями от 06.12.2016. [Instructions for the medical use of Lenvima® (lenvatinib): RU PL – 003398 dated 29.12.2015, as amended on 06.12.2016 (In Russ.)].; https://www.malignanttumors.org/jour/article/view/395

الاتاحة: https://www.malignanttumors.org/jour/article/view/395
https://doi.org/10.18027/2224-5057-2017-3-89-92

المؤلفون: G. Y. Kharkevich, L. V. Demidov, Г. Ю. Харкевич, Л. В. Демидов

المصدر: Malignant tumours; № 3 (2017); 62-69 ; Злокачественные опухоли; № 3 (2017); 62-69 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: CTLA-4, ингибиторы блокаторов иммунного ответа, иммунотерапия, PD-1

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/393/339; Thompson J. F., Scolyer R. A., Kefford R. F. Cutaneous melanoma, Lancet, 2005, Vol. 365, No. 9460, pp. 687–701.; de Vries E., Bray F. I., Coebergh J. W., Parkin D. M. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia, Int. J. Cancer, 2003, Vol. 107, No. 1, pp. 119–126.; World Health Organization. Skin cancers. Available from: http://www.who.int / uv / faq / skincancer / en / index1. html, Accessed March 11, 2017.; Balch C. M., Soong S. J., Gershenwald J. E. et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system, J. Clin. Oncol., 2001, Vol. 16, No. 19, pp. 3622–3634.; Barth A., Wanek L. A., Morton D. L. Prognostic factors in 1,521 melanoma patients with distant metastases, J. Am. Coll. Surg., 1995, Vol. 181, No. 3, pp. 193–103.; Каприн А. Д., Старинский В. В., Петрова В. В. Состояние онкологической помощи населению России в 2016 году. Москва: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 266 с. [Kaprin A. D., Starinskiy V. V., Petrova V. V. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2016 godu, Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMIRTs” Minzdrava Rossii, 2017, 266 p.]; Fletcher W. S., Pommier R. F., Lum S., Wilmarth T. J. Surgical treatment of metastatic melanoma, Am. J. Surg, 1998, Vol. 175, No. 5, pp. 413–417.; Lui P., Cashin R., Machado M., Hemels M. et al. Treatments for metastatic melanoma: synthesis of evidence from randomized trials, Cancer Treat Rev., 2007, Vol. 33, No. 8, pp. 665–680.; Maverakis E., Cornelius L. A., Bowen G. M. et al. Metastatic melanoma: a review of current and future treatment options, Acta Derm. Venereol., 2015, Vol. 95, No. 5, pp. 516–524.; Hall R. D., Kudchadkar R. R. BRAF mutations: signalling, epidemiology, and clinical experience in multiple malignancies, Cancer Control, 2014, Vol. 21, No. 3, pp. 221–230.; Giovanni P., Giovanni P., Aldo T. et al. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT and GNAQ melanomas, Dis Markers, 2014, No. 2014, 671283.; Sullivan R., LoRosso P., Boerner S., et al. Achievements and challenges of molecular targeted therapy in melanoma, Am. Soc. Clin. Oncol. Educ. Book, 2015, No. 35, pp. 177–186.; Luke J. J., Ott P. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma, Oncotarget, 2015, Vol. 6, No. 6, pp. 3479–3492.; Antonia S. J., Larkin J., Ascierto P. A. Immuno-oncology combinations: a review of clinical experience and future prospects, Clin. Cancer Res., 2014, Vol. 20, No. 24, pp. 6258–6568.; Shih K., Arkenau H. T., Infante J. R. Clinical impact of checkpoint inhibitors as novel cancer therapies, Drugs, 2014, Vol. 74, No. 17, pp. 1993–2013.; Tsai K. K., Daud A. L. The role of anti-PD-1 / PD-L1 agents in melanoma: progress to date, Drugs, 2015, Vol. 75, No. 6, pp. 563–575.; Hodi F. S., O’Day S. J., McDermott D. F. et al. Improved survival with ipiipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 2010, Vol. 363, No. 8, pp. 711–723.; Deeks E. D. Nivolumab: a review of its use in patients with malignant melanoma, Drugs, 2014, Vol. 74, No. 11, pp. 1233–1239.; Larkin J., Chiarion-Sileni V., Gonzalez R. et al. Combined nivolumab and ipilumumab or monotherapy in untreated melanoma, N. Engl. J. Med., 2015, Vol. 573, No. 1, pp. 21–34.; Wolchok J. D., Kluger H., Callahan M. K. et al. Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 2013, Vol. 369, No. 2, pp. 122–133.; Ascierto P. A., Melero I., Bhatia S. et al. Initial Efficacy of Anti-Lymphocyte Activation Gene-3 (anti – LAG-3; BMS-986016) in Combination With Nivolumabin Patients With Melanoma Previously Treated With Anti – PD-1 / PD-L1 Therapy, J. Clin. Oncol., 2017, No. 35 (suppl.; abstr 9520).; Siu L. L., Steeghs N., Meniawy T. et al. Preliminary Results of a Phase 1 / 2a Study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor – related gene [GITR] agonist) Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors, 2017, No. 35 (suppl.; abstr 104).; Perez R. P., Riese J. M., Lewis K. D. et al. Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I / II results of ECHO-204, J. Clin. Oncol., 2017, No. 35, (suppl; abstr 3003).; Topalian S. L., Hodi S. F., Brahmer J. R. et al. Safety, Activity, and Immune Correlates of Anti – PD-1 Antibody in Cancer, N. Engl. J. Med., 2012, Vol. 366, No. 26, pp. 2443–2453.; Hodi F. S., Kluger H., Sznol M. et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial, Oral presentation at: AACR Annual Meeting 2016, abstr. CT001.; Weber J. S., D’Angelo S. P., Minor D. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 2015, Vol. 16, No. 4, pp. 375–384.; Larkin J., Minor D., D’Angelo S. et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial, J. Clin. Oncol., 2017 Jul 3, JCO2016718023 [Epub ahead of print].; Robert C., Long G. V., Brady B. et al. Nivolumab in previously untreated melanoma whithout BRAF mutation, N. Eng. J. Med., 2015, Vol. 372, No. 4, pp. 320–330.; Kluger H. M., Sznol M., Callahan M. K. et al. Survival, response duration, and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL) [abstract], Pigment Cell Melanoma Res., 2014, Vol. 27, No. 6, p. 1203.; Postow M. A., Chesney J., Pavlick A. C. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N. Engl. J. Med., Vol. 372, No. 21, pp. 2006–2017.; Hodi F. S., Chesney J., Pavlick A. C. et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, lancet Oncol., 2016, Vol. 17, No. 11, pp. 1558–1568.; Wolchok J. D., Chiarion-Sileni V., Gonzales R. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N. Engl. J. Med., Sep 2017, pp. 12. DOI:10.1056 / NEJMoa1709684. [Epub ahead of print].; Weber J. S., Hodi F. S., Wolchjok J. D. et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, J. Clin. Oncol., 2017, Vol. 35, No. 7, pp. 785–791.; https://www.malignanttumors.org/jour/article/view/393

الاتاحة: https://www.malignanttumors.org/jour/article/view/393
https://doi.org/10.18027/2224-5057-2017-3-62-69

المؤلفون: I. V. SAMOILENKO, G. Y. KHARKEVICH, L. V. DEMIDOV, И. В. САМОЙЛЕНКО, Г. Ю. ХАРКЕВИЧ, Л. В. ДЕМИДОВ

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2016); 84-92 ; Медицинский Совет; № 10 (2016); 84-92 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2016-10

مصطلحات موضوعية: ипилимумаб, immunooncology, anti-CTLA4, ipilimumab, иммуноонкология

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1409/1367; Coley WB. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med, 1910, 3(Surg Sect): 1-48.; Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res, 1970, 13: 1- 27.; Tirelli U, Carbone A, Monfardini S, Lazzarin A, Alessi E, Pileri S. Malignant tumors in patients with human immunodeficiency virus infection: a report of 580 cases. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 1989, 7(10): 1582-1583.; Varan A, Buyukpamukcu M, Ersoy F, Sanal O, Akyuz C, Kutluk T, Yalcin B. Malignant solid tumors associated with congenital immunodeficiency disorders. Pediatr Hematol Oncol, 2004, 21(5): 441-451.; Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 2003, 9(12): 4296-4303.; Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 1996, 77(7): 1303-1310.; Самойленко И.В., Харкевич Г.Ю., Демидов Л.В. Преодоление иммунной толерантности как способ лечения злокачественных опухолей: новые перспективы. Современная онкология, 2014, 16(1): 42-47./Samoilenko I.V., Kharkevich G.Y., Demidov L.V. Overcoming of immune tolerance as a method to treat malignant tumours: new prospects. Sovremennaya Onkologia, 2014, 16 (1): 42-47.; Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA et al. Mutational heterogeneity in cancer and the search for new cancer- associated genes. Nature, 2013, 499(7457): 214-218.; Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/ PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research, 2013, 19(19): 5300-5309.; van Wijk F, Nierkens S, de Jong W, Wehrens EJ, Boon L, van Kooten P, Knippels LM, Pieters R. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins. J Immunol, 2007, 178(11): 6894-6900.; Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti- CD28 monoclonal antibody TGN1412. The New England journal of medicine, 2006, 355(10): 1018-1028.; Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research, 2015, 21(19): 4286-4293.; Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine, 2010, 363(8): 711-723.; Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 2011, 364(26): 2517-2526.; Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical cancer research: an official journal of the American Association for Cancer Research, 2009, 15(23): 7412-7420.; McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S, Investigators MDX. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2013, 24(10): 2694-2698.; Maio M. Survival amalysis with 5 years of follow up in phase III study of ipilimumab and dacarbazine in metastatic melanoma: ESMO oral presentation 3704. Eur J Cancer, 2013.; Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2015, 33(17): 1889- 1894.; Sherrill B, Wang J, Kotapati S, Chin K. Q-TWiST analysis comparing pilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer 2013, 109(1):8-13.; Самойленко И.В., Харкевич Г.Ю., Демидов Л.В. Применение блокатора рецепторов CTLA4 в лечении больных метастатической мела номой. РМЖ, 2015, 21(1): 4- ./Samoilenko I.V., Kharkevich G.Y., Demidov L.V. Application of CTLA4 receptor blockers in therapy of metastatic melanoma patients. RMZ, 2015, 21 (1): 4-9.; Gilardi L, Colandrea M, Vassallo S, Travaini LL, Paganelli G. Ipilimumab-Induced Immunomedia ted Adverse Events: Possible Pitfalls in18F-FDG PET/CT Interpretation. Clinical nuclear medicine, 2013.; Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer, 2015, 51(18): 2785-2791.; Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS, Investigators MDX. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer, 2013, 119(9): 1675-1682.; Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine, 2015, 373(1): 23-34.; Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine, 2015, 372(26): 2521-2532.; Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Schadendorf D, Ferrucci PF, Smylie M et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016, 34(suppl; abstr 9505).; Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Ferrucci PF, Smylie M et al.Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatmentnaive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Journal of clinical oncology: official journal of the American Society ofClinical Oncology 2015, 33(suppl; abstr LBA1).; Atkins MB, Choueiri TK, Hodi FS, Thompson JA, Hwu W-J, McDermott DF, Brookes M, Tosolini A, Ebbinghaus S, Yang Z et al. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015, 33(suppl; abstr 3009).; Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Jr., Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. The Lancet Oncology 2016, 17(7): 943-955.; Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2001, 19(16): 3622-3634.; https://www.med-sovet.pro/jour/article/view/1409

الاتاحة: https://www.med-sovet.pro/jour/article/view/1409
https://doi.org/10.21518/2079-701X-2016-10-84-92

المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, A. H. Bekyashev, L. V. Demidov, G. Yu. Kharkevich, S. M. Banov, I. V. Samoylenko, K. А. Baryshnikov, K. V. Orlova, I. А. Utyashev, N. N. Petenko, I. G. Markina, E. A. Moskvina, S. V. Medvedev, Д. Р. Насхлеташвили, В. А. Горбунова, А. Х. Бекяшев, Л. В. Демидов, Г. Ю. Харкевич, С. М. Банов, И. В. Самойленко, К. А. Барышников, К. В. Орлова, И. А. Утяшев, Н. В. Петенко, И. Г. Маркина, Е. А. Москвина, С. В. Медведев

المصدر: Malignant tumours; № 4s1 (2016); 67-73 ; Злокачественные опухоли; № 4s1 (2016); 67-73 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: лучевая терапия, таргетная терапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/290/260; Schouten LJ, Rutten J, Huveneers HA et al. Incidence of brain colon, kidney, and lung and melanoma. Cancer 2002;94:2698-2705.; Tabouret E, Chinot O, Metellus P, et al. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012; 32: 4655-4662.; Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002; 38: 487-496.; Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295-1304.; Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for theRev 2006;3: CD003869.; Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-3650.; D'Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014; 6: 101-114.; Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-346.; Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–2139.; Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010; 12: 1193–1199.; Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor – mutant non-small cell lung cancer. Lung Cancer. 2016; 93: 59–68.; Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013; 82: 282–287.; Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never- smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009; 65: 351–354.; Naskhletashvili D. R., Gorbounova V. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib in the treatment of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). 37th ESMO Congress, Austria, Vienna, 28 September – 02 October 2012, abstract 1330.; Насхлеташвили Д. Р., Горбунова В. А., Бычков М. Б., Бекяшев А. Х., Карахан В. Б., Алешин В. А., Белов Д. М., Москвина Е. А. Гефитиниб («Иресса») в лечении метастазов немелкоклеточного рака легкого в головном мозге. Опухоли головы и шеи, № 3, 2012 год, стр. 63–65.; Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of their reversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015; 10: 156–163.; Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4: 1046–1061.; Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR- mutated non-small-cell lung cancer. N Engl J Med. 2015; 372: 1700–1709.; Sakagami H, Konagai S, Yamamoto H, et al. ASP8273, a novel mutantselective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. Cancer Res. 2014; 74 (suppl; abstr 1728).; Lee KO, Cha MY, Kim M, et al. Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor. Cancer Res. 2014;74 (suppl; abstr LB-100).; Zeng Q, Wang J, Cheng Z, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015; 58: 8200–8215.; Bohn JP, Pall G, Stockhammer G, et al. Targeted therapies for the treatment of brain metastases in solid tumors. Target Oncol. Epub 2016 Jan 29.; Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALKS-rearranged non-small- cell lung cancer and brain metastases. J Clin Oncol. 2015; 33: 1881–1888.; Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small- cell lung cancer and brain metastasis. J Clin Oncol. 2016; 34: 123–129.; Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011; 29: e443-e445.; Shaw AT, Kim DW, Mehra R, et al. Ceritinibin ALK-rearranged non-small cell lung cancer. New Engl J Med. 2014; 370: 1189–1197.; Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013; 14: 590–598.; Shaw A, Mehra R, Tan DSW, et al. BM-32 Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND-1 trial. Neuro Oncol. 2014; 16: v39.; Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014; 74: 1023–1028.; Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib resistant ALK-rearranged non- small-cell lung cancer (AF-002JG): results from the dose- finding portion of a phase 1/2 study. Lancet Oncol. 2014; 15: 1119–1128.; Camidge DR, Bazhenova L, Salgia R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2015; 33 (suppl; abstr 8062).; Kerstein D, Gettinger S, Gold K, et al. LBA4: evaluation of anaplastic lymphoma kinase (ALK) inhibitor brigatinib [AP26113] in patients with ALK+ non-small cell lung cancer (NSCLC) and brain metastases. Ann Oncol. 2015; 26: i60-i61.; Dawood S, Lei X, Litton JK, et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor- negative breast cancer. Cancer. 2012; 118: 4652–4659.; Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcome sin patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113: 2638–2645.; Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from regist HER. Clin Cancer Res. 2011; 17: 4834–4843.; Olson EM, Abdel-Rasoul M, Maly J, et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013; 24: 1526–1533.; Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013; 14: 244–248.; Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006; 15: 219–225.; Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87: 586–592.; Tamura K, Kurihara H, Yonemori K, et al. 64Cu-DOTA- trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med.2013; 54: 1869–1875.; Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol. 2007; 85: 311–317.; Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66: 1630–1639.; Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-3-chloro-4-[(3-fluorobenzyl)oxy] phenyl-6-[5-([2-(methylsulfonyl) ethyl]aminomethyl)-2-furyl]- 4-quinazolinamine; GW572016). Drug Metab Dispos. 2009; 37: 439–442.; NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009; 15: 1452–1459.; Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabin ein patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14: 64–71.; Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А., Бекяшев А. Х., Карахан В. Б., Михина З. П., Медведев С. В. Лекарственная терапия больных раком молочной железы с метастатическим поражением головного мозга. Российское общество клинической онкологии, официальная газета общества, 2015 год, № 1, стр. 10–11.; Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А. Современные возможности таргетной терапии в лечении больных раком молочной железы с гиперэкспрессией Her-2/neu и с метастатическим поражением головного мозга. Вопросы онкологии, № 3, 2013 год, том 59, стр. 347–351.; Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372: 724–734.; Bartsch R, Berghoff AS, Vogl U, et al. Activity of T-DM1 in Her2- positive breast cancer brain metastases. Clin Exp Metastasis. 2015; 32: 729–737.; Long GV, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am Soc Clin Oncol Educ Book. 2013; 33: 393–398.; Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118: 4014–4023.; Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379: 1893–1901.; Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 1087–1095.; Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014; 50: 611–621.; Kefford R, Malo M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open label, single arm, phase 2, multicenter study. Paper presented at: 2013 Society for Melanoma Research Congress; November 2013; Philadelphia, PA.; Berghoff AS, Preusser M. The future of targeted therapies for brain metastases. Future Oncol. 2015; 11: 2315–2327.; Vyshak A. Venur, MD, and Manmeet S. Ahluwalia. Targeted Therapy in Brain Metastases: Ready for Primetime? 2016 ASCO EDUCATIONAL BOOK, e123-e130.; https://www.malignanttumors.org/jour/article/view/290; undefined

الاتاحة: https://www.malignanttumors.org/jour/article/view/290

المؤلفون: L. V. Demidov, G. Yu. Kharkevich, I. V. Timofeyev, I. G. Markina, V. B. Matveev, N. A. Vetrova, L. A. Kostyakova, Л. В. Демидов, Г. Ю. Харкевич, И. В. Тимофеев, И. Г. Маркина, В. Б. Матвеев, Н. А. Ветрова, Л. А. Костякова

المصدر: Cancer Urology; Том 2, № 4 (2006); 15-18 ; Онкоурология; Том 2, № 4 (2006); 15-18 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2006-2-4

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1146/1032; Atzpodien J., Kirchner H., Jonas U. et al. Interleukin-2 and interferon-α 2a based immunotharapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:7.; Calugiuri M.A. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Am J Clin Oncol 1994;17:199.; Gitlitz B., Figlin R. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 2003;30(3):589–600.; Lissoni P., Barni S., Ardizzoia A. et al. A randomized study of low-dose interleukin-2 plus interferon-alpha first line therapy for metastatic RCC. Tumor 1993;79:397–400.; Margolin K. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27(2): 194–203.; Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recombinant interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998;338:1272.; https://oncourology.abvpress.ru/oncur/article/view/1146

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1146
https://doi.org/10.17650/1726-9776-2006-2-4-15-18